News Releases
NervGen Presenting Study Design for Upcoming Phase 1b/2a in Alzheimer’s Disease at the 2022 Alzheimer’s Association International Conference
Vancouver, Canada August 2, 2022 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair from a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke
NervGen Pharma Grants Stock Options
Vancouver, Canada. July 15, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors
Vancouver, Canada. July 14, 2022— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug
NervGen Pharma Provides Update On Closing Of Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. July 11, 2022— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX:
NervGen Pharma Corp. Announces US$15MM Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. June 30, 2022— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX:
NervGen Pharma Grants Stock Options
Vancouver, British Columbia–(Newsfile Corp. – May 31, 2022) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Panel discussion will focus on the successful translation of NervGen’s lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events
NervGen Pharma Appoints Craig Thompson to the Board of Directors
30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at Pfizer Experience on 16 development stage products, 15 commercial stage
NervGen Pharma Grants Stock Options
Vancouver, Canada. April 6, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Human subjects now being enrolled in the second cohort of multiple ascending dose portion of the study NVG-291 dose administered in the first cohort is
NervGen Pharma to Present at 2022 Virtual Growth Conference Presented by Maxim Group / Engages Apaton Finance to Provide Investor Relations Services in Europe
Vancouver, Canada. March 23, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for
NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical Trial of NVG-291
The dose of NVG-291 in the first cohort is already above the highest corresponding dose that resulted in dramatic functional improvements in animal models Approval
NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study
Vancouver, Canada. February 28, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing